Background Vaccination coverage rates for seasonal influenza are not meeting national and international targets. Here, we investigated whether the 2009/2010 A/H1N1 pandemic influenza affected the uptake of influenza vaccines. Methodology/Principal Findings In December 2009/January 2010 and April 2010, 500 randomly selected members of the general public in Germany, France, the United States, China, and Mexico were surveyed by telephone about vaccination for seasonal and A/H1N1 pandemic influenza. Also, in April 2010, 100 randomly selected general practitioners were surveyed. Adult vaccine coverage in December 2009/January 2010 for A/H1N1 pandemic and seasonal influenza were, respectively, 12% and 29% in France, 11% and 25% in Germany, 41% and 46% in the US, 13% and 30% in Mexico, and 12% and 10% in China. Adult uptake rates in April 2010 were higher in Mexico but similar or slightly lower in the other countries. Coverage rates in children were higher than in adults in the US, Mexico, and China but mostly lower in Germany and France. Germans and French viewed the threat of A/H1N1 pandemic influenza as low to moderate, whereas Mexicans, Americans, and Chinese viewed it as moderate to serious, opinions generally mirrored by general practitioners. The recommendation of a general practitioner was a common reason for receiving the pandemic vaccine, while not feeling at risk and concerns with vaccine safety and efficacy were common reasons for not being vaccinated. Inclusion of the A/H1N1 pandemic strain increased willingness to be vaccinated for seasonal influenza in the United States, Mexico, and China but not in Germany or France. Conclusions/Significance The 2009/2010 A/H1N1 influenza pandemic increased vaccine uptake rates for seasonal influenza in Mexico but had little effect in other countries. Accurate communication of health information, especially by general practitioners, is needed to improve vaccine coverage rates.
References
[1]
World Health Organization (2009) Influenza (seasonal) Geneva: World Health Organization Media Centre.
[2]
World Health Organization (2003) Resolution of the World Health Assembly WHA 56.19. Prevention and control of influenza pandemics and annual epidemics; 19–28 May; Geneva.
[3]
The Council of the European Union (2009) Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union L348: 71–72.
[4]
Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, et al. (2010) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59: 1–62.
[5]
Centers for Disease Control (2011) Healthy People 2020 Summary of Objectives.
[6]
Centers for Disease Control and Prevention (2011) Influenza vaccination coverage levels. 2010–11 Influenza prevention & control recommendations.
[7]
Johnson DR, Nichol KL, Lipczynski K (2008) Barriers to adult immunization. Am J Med 121: S28–35.
[8]
Uscher-Pines L, Maurer J, Kellerman A, Harris KM (2010) Healthy young and middle age adults: what will it take to vaccinate them for influenza? Vaccine 28: 7420–7422.
[9]
Blank PR, Schwenkglenks M, Szucs TD (2009) Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 58: 446–458.
[10]
Holm MV, Blank PR, Szucs TD (2007) Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006. BMC Infect Dis 7: 144.
[11]
World Health Organization (2010) H1N1 in post-pandemic period.
[12]
World Health Organization (2010) Pandemic (H1N1) 2009 - update 112.
[13]
Walter D, Bohmer MM, Heiden M, Reiter S, Krause G, et al. (2011) Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive cross-sectional surveys. Vaccine 29: 4008–4012.
[14]
Weil-Olivier C, Lina B (2011) Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009–2010 season. Vaccine 29: 7075–7079.
[15]
Bone A, Guthmann JP, Nicolau J, Levy-Bruhl D (2010) Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: results of a national vaccination campaign. Vaccine 28: 8157–8161.
[16]
Vaux S, Van Cauteren D, Guthmann JP, Le Strat Y, Vaillant V, et al. (2011) Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health 11: 30.
[17]
Blank PR, Schwenkglenks M, Szucs TD (2008) Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 8: 272.
[18]
Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, et al. (2010) Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Euro Surveill 15.
[19]
Aburto NJ, Pevzner E, Lopez-Ridaura R, Rojas R, Lopez-Gatell H, et al. (2010) Knowledge and adoption of community mitigation efforts in Mexico during the 2009 H1N1 pandemic. Am J Prev Med 39: 395–402.
[20]
Hawley C (2009 April 25) Swine flu spreads panic in Mexico City. USA Today.
[21]
Coker R (2009) Swine flu. Bmj 338: b1791.
[22]
Chor JS, Pada SK, Stephenson I, Goggins WB, Tambyah PA, et al. (2011) Seasonal influenza vaccination predicts pandemic H1N1 vaccination uptake among healthcare workers in three countries. Vaccine 29: 7364–7369.
[23]
Maurer J, Harris KM, Parker A, Lurie N (2009) Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine 27: 5732–5734.
[24]
Seale H, Heywood AE, McLaws ML, Ward KF, Lowbridge CP, et al. (2011) Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC Infect Dis 10: 99.
[25]
Sypsa V, Livanios T, Psichogiou M, Malliori M, Tsiodras S, et al. (2009) Public perceptions in relation to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional telephone survey. Euro Surveill 14.
[26]
Wong SY, Wong EL, Chor J, Kung K, Chan PK, et al. (2011) Willingness to accept H1N1 pandemic influenza vaccine: a cross-sectional study of Hong Kong community nurses. BMC Infect Dis 10: 316.
[27]
Ropero-Alvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Andrus JK (2009) Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 9: 361.
[28]
Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, et al. (2011) Acceptance of Intanza(R) 9 mg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 28: 640–649.
[29]
Schwarzinger M, Flicoteaux R, Cortarenoda S, Obadia Y, Moatti JP (2010) Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance? PLoS One 5: e10199.
[30]
Van Buynder PG, Carcione D, Rettura V, Daly A, Woods E (2011) Marketing paediatric influenza vaccination: results of a major metropolitan trial. Influenza Other Respi Viruses 5: 33–38.
[31]
Yoo BK, Holland ML, Bhattacharya J, Phelps CE, Szilagyi PG (2010) Effects of mass media coverage on timing and annual receipt of influenza vaccination among Medicare elderly. Health Serv Res 45: 1287–1309.
[32]
EphMRA (European Pharmaceutical Market Research Association).
[33]
(1998) The European Commission's Directive on Data Protection 1998 (collection, use, and retention of personal information from all countries).
[34]
(2005) Esomar World research codes & guidelines: ICC/ESOMAR International Code of Marketing and Social Research Practice.
[35]
Safe Harbor Privacy Principles. ICO United Kingdom Information Commissioner's Office registration (ID PZ2532216): Lithuania State Department of Data Protection registration (ID P4826).
[36]
Choi BC (2004) Computer assisted telephone interviewing (CATI) for health surveys in public health surveillance: methodological issues and challenges ahead. Chronic Dis Can 25: 21–27.